MX2015010967A - Formulaciones transdermicas de laquinimod. - Google Patents

Formulaciones transdermicas de laquinimod.

Info

Publication number
MX2015010967A
MX2015010967A MX2015010967A MX2015010967A MX2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
laquinimod
optionally
transdermal patch
provides
Prior art date
Application number
MX2015010967A
Other languages
English (en)
Inventor
Dirk Schenk
Ralph Stefan
Tanja Pries
Hans-Juergen Mika
Sabine Prohl
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015010967A publication Critical patent/MX2015010967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Esta invención proporciona un parche transdérmico que comprende: a) una capa de respaldo; b) un revestimiento; c) opcionalmente, una membrana altamente porosa; y d) una composición farmacéutica que comprende: (i) opcionalmente, un adhesivo sensible a la presión en una cantidad de hasta aproximadamente 95% de peso de la composición farmacéutica, (ii) el laquinimod en una cantidad de aproximadamente 0.1-20% de peso de la composición farmacéutica, y (iii) opcionalmente, uno o más potenciadores de permeación en una cantidad total de hasta aproximadamente 70% de peso de la composición farmacéutica. Esta invención también proporciona un método para suministrar el laquinimod a través de la piel de un sujeto y para tratar a un sujeto humano afligido con una forma de esclerosis múltiple que comprende la administración de un parche transdérmico a la piel del sujeto como se describe en la presente. Esta invención además proporciona un parche transdérmico como se describe en la presente para usarse en un tratamiento de un sujeto humano afligido con una forma de esclerosis múltiple.
MX2015010967A 2013-03-14 2014-03-13 Formulaciones transdermicas de laquinimod. MX2015010967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (1)

Publication Number Publication Date
MX2015010967A true MX2015010967A (es) 2015-10-26

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010967A MX2015010967A (es) 2013-03-14 2014-03-13 Formulaciones transdermicas de laquinimod.

Country Status (8)

Country Link
US (1) US20160038435A1 (es)
EP (1) EP2968203A1 (es)
JP (1) JP2016513665A (es)
CA (1) CA2900977A1 (es)
HK (1) HK1220125A1 (es)
IL (1) IL240557A0 (es)
MX (1) MX2015010967A (es)
WO (1) WO2014152009A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018485A8 (pt) 2012-02-03 2017-07-11 Teva Pharma Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20170071869A1 (en) * 2014-03-14 2017-03-16 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
KR101440982B1 (ko) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
ES2377149T3 (es) 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CN104311486A (zh) 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
RS54328B1 (en) 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781239B (zh) 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
KR20160129093A (ko) 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
JP2013535437A (ja) 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
EA201390074A1 (ru) 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
EA201390827A1 (ru) 2010-12-07 2013-12-30 Тева Фармасьютикал Индастриз Лтд. Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом

Also Published As

Publication number Publication date
EP2968203A1 (en) 2016-01-20
CA2900977A1 (en) 2014-09-25
IL240557A0 (en) 2015-10-29
JP2016513665A (ja) 2016-05-16
HK1220125A1 (zh) 2017-04-28
WO2014152009A1 (en) 2014-09-25
US20160038435A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
PH12015502550A1 (en) Transdermal delivery system
MX366560B (es) Parche adhesivo con composicion antimicrobiana.
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
GB2520897A (en) Compositions and methods for treating cutaneous scarring
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
PH12015501169A1 (en) Transdermal delivery system
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
MX2018009575A (es) Sistema y metodo para conservar y suministrar un gas terapeutico a una herida.
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
MY184693A (en) Bilayer hydrocolloid films containing therapeutic agents
EA201792165A1 (ru) Устройство для ухода за полостью рта
MY182620A (en) Topical formulations of heparin
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
MY162768A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
MY197404A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
MX2017005046A (es) Metodo y articulos para inhibir las contracciones vesicales.
BR112016006842A2 (pt) dispositivos de distribuição transdérmica de dexme-detomidina e métodos de uso dos mesmos